Regeneron Pharmaceuticals Inc. sell dimontalban
Start price
20.04.20
/
50%
€528.00
Target price
23.08.20
€290.00
Performance (%)
-1.52%
End price
23.08.20
€520.00
Summary
This prediction ended on 23.08.20 with a price of €520.00. With a performance of -1.52%, the SELL prediction by dimontalban was trending in the right direction. dimontalban has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 4.483% | 4.483% | -2.144% | -9.352% |
| iShares Core DAX® | -1.020% | 0.271% | 13.941% | 56.827% |
| iShares Nasdaq 100 | -3.122% | -1.929% | 1.920% | 83.028% |
| iShares Nikkei 225® | 0.649% | 6.582% | 21.176% | 50.695% |
| iShares S&P 500 | -0.142% | -0.295% | 1.363% | 57.560% |
Comments by dimontalban for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Sell mit Kursziel 290,0